Bal Pharma Limited (NSE:BALPHARMA)

Market Cap	1.72B +28.4%
Revenue (ttm)	3.34B +13.5%
Net Income	72.07M +0.7%
EPS	4.50 -1.7%
Shares Out	n/a
PE Ratio	23.84
Forward PE	n/a
Dividend	1.20 (1.12%)
Ex-Dividend Date	Sep 17, 2026

Volume	17,112
Open	106.25
Previous Close	108.28
Day's Range	106.25 - 108.99
52-Week Range	60.00 - 124.60
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2026

About Bal Pharma

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 939
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BALPHARMA

Financial Performance

In fiscal year 2026, Bal Pharma's revenue was 3.12 billion, an increase of 2.83% compared to the previous year's 3.03 billion. Earnings were 62.84 million, a decrease of -12.91%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 24, 2026

Data Sources Report a data error